SCHEMBL171348

SCHEMBL171348

CCCCOc1ccc(-c2[nH]c3ccc(OCCCC)cc3c2C)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 2/20 0.64
CTSV O60911 1/20 0.52
CTSL P07711 1/20 0.52
CYP2D6 P10635 6/20 0.49
CYP2C9 P11712 5/20 0.49
CYP2C19 P33261 5/20 0.49
CYP3A4 P08684 4/20 0.49
ALOX5 P09917 1/20 0.49
CYP1A2 P05177 4/20 0.46
CYP19A1 P11511 3/20 0.46
KDM4E B2RXH2 4/20 0.44
GPR84 Q9NQS5 1/20 0.44
HTR1D P28221 6/20 0.44
HTR1B P28222 6/20 0.44
HTR1A P08908 4/20 0.43
ALDH1A1 P00352 2/20 0.43
HSD17B10 Q99714 2/20 0.43
HPGD P15428 1/20 0.43
MEN1 O00255 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14546539 0.92 NR1I2 (0.55) NR1I2CTSVCTSLCYP2D6CYP2C9
SCHEMBL14608693 0.89 NR1I2 (0.53) NR1I2CTSVCTSLCYP2D6CYP2C9
SCHEMBL10040975 0.89 NR1I2 (0.51) NR1I2CTSVCTSLCYP2D6CYP2C9
SCHEMBL12966419 0.88 NR1I2 (0.60) NR1I2CTSVCTSLCYP2D6CYP2C9
SCHEMBL14608490 0.86 NR1I2 (0.50) NR1I2CTSVCTSLCYP2D6CYP2C9
SCHEMBL12966402 0.84 CTSV (0.51) NR1I2CTSVCTSLCYP2D6CYP2C9
SCHEMBL13922106 0.83 NR1I2 (0.54) NR1I2CYP2D6CYP2C9CYP2C19CYP3A4
SCHEMBL12966379 0.82 MAPT (0.50) NR1I2CTSVCTSLCYP2D6CYP2C9
SCHEMBL4565516 0.82 ALOX5 (0.61) NR1I2CYP2D6CYP2C9CYP2C19CYP3A4
SCHEMBL10605076 0.80 ALOX5 (0.70) NR1I2CTSVCTSLCYP2D6ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230158152-A1 PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME MEDSHINE DISCOVERY INC. (CN) 2023-05-25 US disclosed
US-8889896-B2 Process for the preparation of bazedoxifene acetate and intermediates thereof Divi's Laboratories, Ltd. (IN) 2014-11-18 US disclosed
US-20140329784-A1 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS WYETH LLC (US) 2014-11-06 US disclosed
US-8815934-B2 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations WYETH LLC (US) 2014-08-26 US disclosed
US-20130289296-A1 NOVEL PROCESS FOR THE PREPARATION OF BAZEDOXIFENE ACETATE AND INTERMEDIATES THEREOF DIVI'S LABORATORIES LTD. (IN) 2013-10-31 US disclosed
US-20120330008-A1 NOVEL PROCESS FOR THE PREPARATION OF BAZEDOXIFENE ACETATE AND INTERMEDIATES THEREOF DIVI'S LABORATORIES LIMITED (IN) 2012-12-27 US disclosed
US-20120252769-A1 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS WYETH LLC (US) 2012-10-04 US disclosed
EP-2118058-B9 METHOD FOR THE PREPARATION OF 5-BENZYLOXY-2-(4-BENZYLOXPHENYL)-3-METHYL-1H-INDOLE ZENTIVA KS (CZ) 2012-03-28 EP disclosed
EP-2426105-A1 Process for the preparation of 5-benzyloxy-2-(4-benzyloxyphenyl)-3-methyl-1h-indole Divi's Laboratories Limited (IN) 2012-03-07 EP disclosed
US-8034807-B2 Salts of bazedoxifene ZENTIVA K.S. (CZ) 2011-10-11 US disclosed
US-20090176764-A1 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLES AS ESTROGENIC AGENTS WYETH (US) 2009-07-09 US disclosed
WO-2009012734-A2 NEW SALTS OF BAZEDOXIFENE ZENTIVA A.S. (CZ) 2009-01-29 WO disclosed
US-7449455-B2 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents WYETH (US) 2008-11-11 US disclosed
WO-2008098527-A1 METHOD FOR THE PREPARATION OF 5-BENZYLOXY-2-(4-BENZYLOXPHENYL)-3-METHYL-1H-INDOLE ZENTIVA A.S. (CZ) 2008-08-21 WO disclosed
US-20080021017-A1 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents WYETH (US) 2008-01-24 US disclosed
US-7247624-B2 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents WYETH (US) 2007-07-24 US disclosed
US-20070142361-A1 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations WYETH (US) 2007-06-21 US disclosed
US-20070135396-A1 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations WYETH (US) 2007-06-14 US disclosed
US-20070135397-A1 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations WYETH (US) 2007-06-14 US disclosed
US-20070054895-A1 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents WYETH (US) 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329784-A1 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS ESR2, ESR1, CYP19A1 NR1I2 197/4885CTSV 3372/4885CTSL 4392/4885
US-20120330008-A1 NOVEL PROCESS FOR THE PREPARATION OF BAZEDOXIFENE ACETATE AND INTERMEDIATES THEREOF CYP19A1, HSD17B11, SULT1E1 NR1I2 513/4885CTSV 4601/4885CTSL 4526/4885
US-20120252769-A1 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLE AND ESTROGEN FORMULATIONS ESR2, ESR1, CYP19A1 NR1I2 197/4885CTSV 3372/4885CTSL 4392/4885
US-20070135397-A1 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations ESR2, ESR1, CYP19A1 NR1I2 197/4885CTSV 3372/4885CTSL 4392/4885
US-20230158152-A1 PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME PSMA6, PSMC1, PSMA1 NR1I2 2617/4885CTSV 232/4885CTSL 283/4885
US-20070135396-A1 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations ESR2, ESR1, CYP19A1 NR1I2 197/4885CTSV 3372/4885CTSL 4392/4885
US-20130289296-A1 NOVEL PROCESS FOR THE PREPARATION OF BAZEDOXIFENE ACETATE AND INTERMEDIATES THEREOF CYP19A1, HSD17B11, SULT1E1 NR1I2 513/4885CTSV 4601/4885CTSL 4526/4885
US-20070142361-A1 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations ESR1, ESR2, CYP19A1 NR1I2 185/4885CTSV 3411/4885CTSL 4433/4885
US-20090176764-A1 2-PHENYL-1-[4-(2-AMINOETHOXY)-BENZYL]-INDOLES AS ESTROGENIC AGENTS BRCA1, ESR2, PKD2 NR1I2 987/4885CTSV 1933/4885CTSL 1407/4885
US-20080021017-A1 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents BRCA1, PKD2, CYP19A1 NR1I2 1260/4885CTSV 1958/4885CTSL 1244/4885
US-20070054895-A1 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents ESR2, GPER1, ESR1 NR1I2 125/4885CTSV 4702/4885CTSL 4739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.